𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

✍ Scribed by André, Thierry; Boni, Corrado; Mounedji-Boudiaf, Lamia; Navarro, Matilde; Tabernero, Josep; Hickish, Tamas; Topham, Clare; Zaninelli, Marta; Clingan, Philip; Bridgewater, John; Tabah-Fisch, Isabelle; de Gramont, Aimery

Book ID
120216781
Publisher
Massachusetts Medical Society
Year
2004
Tongue
English
Weight
121 KB
Volume
350
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant chemotherapy with oxaliplatin,
Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer: Abstracted from: André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51
📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 213 KB
Capecitabine plus oxaliplatin (XELOX) ve
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
✍ Michel Ducreux; Jaafar Bennouna; Mohamed Hebbar; Marc Ychou; Gérard Lledo; Thier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 440 KB

## Abstract A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our study was to demonstrate the non‐inferiority of capecitabine plus oxaliplatin (XELOX) __versus__ FOLF